Key Highlights
- Mobia Medical expands board to seven directors
- Zadno to serve on Compensation Committee, replacing an outgoing member
- Recent insider stock purchase by financial leadership reported in filings
Mobia Medical has enhanced its governance by appointing a veteran medical technology leader to its board. The company, which specializes in minimally invasive surgical devices, welcomed Reza Zadno as an independent director. This addition increases the board’s size and brings expertise in surgical robotics and medical device operations to its compensation oversight.
Board Expansion Details
The company has grown its board to seven members with Zadno’s appointment. He will serve on the Compensation Committee, joining existing members who oversee executive pay and related policies. His appointment follows the departure of a previous committee member, though that individual remains on the board.
Mobia Medical confirmed Zadno meets Nasdaq’s independence requirements and has no significant financial ties to the company. As part of the standard director compensation program, he will receive customary fees and protections. Zadno’s career includes leadership positions at several medical device firms.
Until recently, he held a top executive role at PROCEPT BioRobotics, a company focused on surgical robotics. Prior to that, he led Avedro, an ophthalmology business that was later acquired. His experience also includes board service at other healthcare companies, where he contributed to financial and operational oversight.
More recently, he has been involved with investment activities in the technology sector.
Why the Move Matters Now
Mobia Medical’s stock has faced pressure in recent trading periods, reflecting broader challenges in the medical device sector. The company’s performance has drawn attention from investors evaluating its long-term strategy. Adding a director with public-company leadership experience may help address concerns about operational execution and shareholder alignment.
Earlier this year, a financial executive at the company made a notable stock purchase, which some observers viewed as a sign of confidence in the company’s direction.
What Investors Should Watch
The next opportunity for shareholders to assess Zadno’s impact will come at the company’s annual meeting in the coming years, when his board position will be subject to a vote. In the shorter term, market participants will look for signs of how the expanded board influences key initiatives, such as partnerships in surgical technology or efforts to improve financial discipline. The company’s upcoming earnings report may offer early insights into how governance changes are shaping leadership priorities.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...